TY - JOUR
T1 - Coronary bioresorbable vascular scaffold use in the treatment of coronary artery disease
AU - Testa, Luca
AU - Latib, Azeem
AU - Montone, Rocco A.
AU - Colombo, Antonio
AU - Bedogni, Francesco
N1 - Publisher Copyright:
© 2016 American Heart Association, Inc.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Bioresorbable vascular scaffolds (BVS) represent a promising novel approach for the treatment of coronary artery disease. BVS promise to address some of the well-known limitations of current drug-eluting stents, while providing a transient scaffolding of the vessel to prevent acute vessel closure/recoil. Drug elution by BVS prevents neointimal proliferation in a similar fashion to drug-eluting stents, and complete bioresorption is associated with late vessel lumen enlargement, plaque regression, and restoration of vasomotion. Based on the pathophysiological reasons and on the results derived from clinical studies, BVS are increasingly being used in clinical practice. The aim of this review is to provide an overview of the current evidence supporting the use of BVS in clinical practice. In particular, we will discuss the randomized controlled trials and registries evaluating the clinical outcome of these devices, with a special focus on their application in patients with acute coronary syndrome and in specific lesion subsets (bifurcations, chronic total occlusions, and in-stent restenosis).
AB - Bioresorbable vascular scaffolds (BVS) represent a promising novel approach for the treatment of coronary artery disease. BVS promise to address some of the well-known limitations of current drug-eluting stents, while providing a transient scaffolding of the vessel to prevent acute vessel closure/recoil. Drug elution by BVS prevents neointimal proliferation in a similar fashion to drug-eluting stents, and complete bioresorption is associated with late vessel lumen enlargement, plaque regression, and restoration of vasomotion. Based on the pathophysiological reasons and on the results derived from clinical studies, BVS are increasingly being used in clinical practice. The aim of this review is to provide an overview of the current evidence supporting the use of BVS in clinical practice. In particular, we will discuss the randomized controlled trials and registries evaluating the clinical outcome of these devices, with a special focus on their application in patients with acute coronary syndrome and in specific lesion subsets (bifurcations, chronic total occlusions, and in-stent restenosis).
KW - biodegradable polymers
KW - bioresorbable vascular scaffold
KW - coronary artery disease
UR - http://www.scopus.com/inward/record.url?scp=84978877741&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978877741&partnerID=8YFLogxK
U2 - 10.1161/CIRCINTERVENTIONS.116.003978
DO - 10.1161/CIRCINTERVENTIONS.116.003978
M3 - Review article
C2 - 27412870
AN - SCOPUS:84978877741
SN - 1941-7640
VL - 9
JO - Circulation: Cardiovascular Interventions
JF - Circulation: Cardiovascular Interventions
IS - 7
ER -